These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 17286633)

  • 1. Bortezomib-associated rash: a new recognizable and avoidable side-effect.
    Villarrubia B; Betlloch I; Mataix J; Lucas A; Botella C
    Br J Dermatol; 2007 Apr; 156(4):784-5. PubMed ID: 17286633
    [No Abstract]   [Full Text] [Related]  

  • 2. Bortezomib-induced perivascular dermatitis in a patient with multiple myeloma.
    Ozkurt ZN; Sucak GT; Aki SZ; Yağci M; Erdem O
    Cutan Ocul Toxicol; 2009; 28(3):141-3. PubMed ID: 19548772
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Skin lesions induced by bortezomib.
    Pour L; Hajek R; Zdenek A; Krejci M; Krivanova A; Vorlicek J
    Haematologica; 2005 Dec; 90(12 Suppl):ECR44. PubMed ID: 16464759
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bortezomib-induced Sweet syndrome.
    Knoops L; Jacquemain A; Tennstedt D; Theate I; Ferrant A; Van den Neste E
    Br J Haematol; 2005 Oct; 131(2):142. PubMed ID: 16197442
    [No Abstract]   [Full Text] [Related]  

  • 5. Bortezomib-induced skin eruption.
    Sanchez-Politta S; Favet L; Kerl K; Dietrich PY; Piguet V
    Dermatology; 2008; 216(2):156-8. PubMed ID: 18216478
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Images in clinical Medicine. Bortezomib-induced skin lesions.
    Agterof MJ; Biesma DH
    N Engl J Med; 2005 Jun; 352(24):2534. PubMed ID: 15958809
    [No Abstract]   [Full Text] [Related]  

  • 7. Bortezomib-induced cutaneous lesions in multiple myeloma patients: a case report.
    Rodríguez-Martín M; Sáez-Rodríguez M; García-Bustínduy M; Martín-Herrera A; Noda-Cabrera A
    Dermatol Online J; 2008 Nov; 14(11):14. PubMed ID: 19094852
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Late onset of bortezomib-associated cutaneous reaction following herpes zoster.
    Varettoni M; Vassallo C; Borroni G; Mangiacavalli S; Zappasodi P; Rosso R; Lazzarino M; Corso A
    Ann Hematol; 2007 Apr; 86(4):301-2. PubMed ID: 17131123
    [No Abstract]   [Full Text] [Related]  

  • 9. Cutaneous lymphoid perivascular reaction with atypical CD30+ T cells in a patient with multiple myeloma treated with bortezomib.
    Dehesa L; Bastida J; Limeres-González M; Campos-Adsuar C; Gómez-Duaso J
    Clin Exp Dermatol; 2009 Dec; 34(8):e1031-2. PubMed ID: 20055832
    [No Abstract]   [Full Text] [Related]  

  • 10. Sweet-like syndrome induced by bortezomib.
    Kolb-Mäurer A; Kneitz H; Goebeler M
    J Dtsch Dermatol Ges; 2013 Dec; 11(12):1200-2. PubMed ID: 23905772
    [No Abstract]   [Full Text] [Related]  

  • 11. Bortezomib-associated cutaneous vasculitis.
    Garcia-Navarro X; Puig L; Fernández-Figueras MT; Dalmau J; Roe E; Alomar A
    Br J Dermatol; 2007 Oct; 157(4):799-801. PubMed ID: 17635511
    [No Abstract]   [Full Text] [Related]  

  • 12. Persistent supravenous eruption induced by intravenous bortezomib therapy.
    Mataix J; Betlloch I; Palmero F; Romero A
    Br J Dermatol; 2008 Apr; 158(4):863-4. PubMed ID: 18284402
    [No Abstract]   [Full Text] [Related]  

  • 13. Severe pulmonary complications after bortezomib treatment for multiple myeloma: an unrecognized pulmonary vasculitis?
    Pitini V; Arrigo C; Altavilla G; Naro C
    Leuk Res; 2007 Jul; 31(7):1027-8. PubMed ID: 17134751
    [No Abstract]   [Full Text] [Related]  

  • 14. Bortezomib-induced skin lesion.
    Ozcan MA; Alacacioglu I; Piskin O; Lebe B; Turgut N; Ceneli S; Demirkan F; Ozsan GH; Undar B
    Acta Haematol; 2006; 116(3):226-7. PubMed ID: 17016047
    [No Abstract]   [Full Text] [Related]  

  • 15. Cutaneous lesion induced by a subcutaneous administration of bortezomib.
    Obeid KM; Ferrara R; Sharma M
    Clin Lymphoma Myeloma Leuk; 2012 Aug; 12(4):284-6. PubMed ID: 22633164
    [No Abstract]   [Full Text] [Related]  

  • 16. Drug-induced hypersensitivity syndrome after bortezomib treatment for refractory multiple myeloma.
    Hattori N; Adachi D; Nakashima H; Saito B; Nakamaki T; Tomoyasu S
    Leuk Res; 2009 Apr; 33(4):574-7. PubMed ID: 18838167
    [No Abstract]   [Full Text] [Related]  

  • 17. Neutrophilic dermatitis associated with bortezomib in a patient with multiple myeloma.
    Paiva CM; Kurtis B; Mekki M; Newman MA; Singhal S; Lacouture ME
    Ann Oncol; 2007 Oct; 18(10):1744-5. PubMed ID: 17890215
    [No Abstract]   [Full Text] [Related]  

  • 18. Pulmonary fibrosis in a myeloma patient on bortezomib treatment. A new severe adverse effect of a new drug.
    Duek A; Feldberg E; Haran M; Berrebi A
    Am J Hematol; 2007 Jun; 82(6):502-3. PubMed ID: 17301973
    [No Abstract]   [Full Text] [Related]  

  • 19. Bortezomib-induced neurogenic bladder in patients with multiple myeloma.
    Shimura K; Shimazaki C; Taniguchi K; Inaba T; Horiike S; Taniwaki M
    Ann Hematol; 2009 Apr; 88(4):383-4. PubMed ID: 18836719
    [No Abstract]   [Full Text] [Related]  

  • 20. Bortezomib-induced histiocytoid Sweet syndrome.
    Murase JE; Wu JJ; Theate I; Cole GW; Barr RJ; Dyson SW
    J Am Acad Dermatol; 2009 Mar; 60(3):496-7. PubMed ID: 19231647
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.